Advanced Medical Isotope Corporation Begins Producing Fluorine-18

AMIC Granted Radioactive Materials License Paving Way for Startup of Nation's First Proton Compact Linear Accelerator

        Print
| Source: Advanced Medical Isotope Corporation

KENNEWICK, Wash., May 27, 2008 (PRIME NEWSWIRE) -- Advanced Medical Isotope Corporation ("AMIC") (Pink Sheets:ADMD) (http://www.isotopeworld.com), a company engaged in the production and distribution of medical isotopes, has successfully produced Fluorine-18, a first in a series of isotopes that AMIC will begin manufacturing at its Kennewick, WA production facility. AMIC successfully produced the Fluorine-18 after receiving its radioactive materials license, awarded by the state of Washington on May 14, 2008.

"The award of the Radioactive Materials License is a very important milestone for our company," said CEO, Mr. William J. Stokes. "This permit was issued following an in-depth review by state officials of the company's personnel, operations controls, and physical security, which allows us to produce, possess as well as distribute radioisotopes. The license is Washington State's certification of AMIC's professional staff, facilities, and administrative control for properly handling radioactive materials. It allows AMIC to proceed with startup operations of our showcase production center, which is built around the nation's first compact Proton Linear Accelerator used for isotope production."

"The state regulators appeared to be very impressed with our attention to safety and the quality of our staff and facilities," said Dr. Fu-Min Su, AMIC's radiochemistry manager and radiation safety officer.

Immediately following the award of the license, AMIC began the hot functional testing of the linear accelerator, and produced its first batch of radioactive materials on the evening of Friday, May 16, 2008.

"Now that we've accomplished this important milestone, our team is aggressively moving forward to complete the balance of systems testing and startup," said James C. Katzaroff, AMIC's President and Chairman of the Board. "AMIC is on target for a mid-June delivery of our first AMIC-manufactured, pharmaceutical grade product for human use."

About Advanced Medical Isotope Corporation

Advanced Medical Isotope Corporation (AMIC) is a medical isotope production company engaged in the production and distribution of medical isotopes and medical isotope in vivo delivery systems for advanced diagnostic and non-surgical therapeutic application. AMIC's goal is to empower physicians, medical researchers, and ultimately patients by providing them with essential medical isotopes that, until now, have not been feasible or economical, in an effort to detect and cure human disease. For more information, please visit our website, www.isotopeworld.com.

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control.

Advanced Medical Isotope Corporation
James C. Katzaroff
509-736-4000

The Investor Relations Group
Erika Moran 
Lynn Granivto
Steven Melfi
212-825-3210